[et_pb_section fb_built=”1″ _builder_version=”3.22.7″ custom_padding=”||5px|||”][et_pb_row _builder_version=”3.25″][et_pb_column type=”4_4″ _builder_version=”3.25″ custom_padding=”|||” custom_padding__hover=”|||”][et_pb_text _builder_version=”3.27.4″]<\/p>\n
[\/et_pb_text][\/et_pb_column][\/et_pb_row][\/et_pb_section][et_pb_section fb_built=”1″ specialty=”on” _builder_version=”3.22.3″ custom_padding=”24px|0px|25px|0px|false|false”][et_pb_column type=”3_4″ specialty_columns=”3″ _builder_version=”3.25″ custom_padding=”|||” custom_padding__hover=”|||”][et_pb_row_inner _builder_version=”3.25″][et_pb_column_inner saved_specialty_column_type=”3_4″ _builder_version=”3.25″ custom_padding=”|||” custom_padding__hover=”|||”][et_pb_blurb title=”Editoral in Hungarian ” url=”https:\/\/mppt.hu\/magazin\/pdf\/xiv-evfolyam-3-szam\/szerklevel%20kovacs.pdf” url_new_window=”on” image=”https:\/\/mppt.hu\/wp-content\/uploads\/2019\/04\/pdf.png” icon_placement=”left” image_max_width=”105%” content_max_width=”1100px” _builder_version=”3.22.7″ header_font=”||||||||” header_font_size=”17px” header_line_height=”1.3em” body_font=”||on||||||” body_line_height=”1.3em” link_option_url=”https:\/\/mppt.hu\/magazin\/pdf\/xiv-evfolyam-3-szam\/szerklevel kovacs.pdf” link_option_url_new_window=”on”]<\/p>\n
G\u00e1bor Kov\u00e1cs<\/p>\n
[\/et_pb_blurb][et_pb_toggle title=”Abstract” closed_toggle_text_color=”#000000″ closed_toggle_background_color=”rgba(0,0,0,0)” icon_color=”#0c71c3″ _builder_version=”3.22.7″ title_font=”|600|||||||” title_letter_spacing=”1px” text_orientation=”justified” custom_padding=”0px||10px” border_width_all=”0px” border_width_bottom=”1px”]<\/p>\n
Az elm\u00falt \u00e9vek szerkeszt\u0151s\u00e9gi leveleinek szerz\u0151i a farmakol\u00f3gia-pszichofarmakol\u00f3gia-neurofarmakol\u00f3gia t\u00e1rgy\u00e1ban a t\u00e1gabb \u00e9rtelemben vett \u00e1ttekint\u00e9seken t\u00falmen\u0151en megfogalmazt\u00e1k saj\u00e1t v\u00e9lem\u00e9ny\u00fcket is az \u00e9rintett t\u00e9m\u00e1ban. Pesszimista \u00e9s optimista megk\u00f6zel\u00edt\u00e9sekkel egyar\u00e1nt tal\u00e1lkozhattunk, el\u0151bbieket tal\u00e1n ink\u00e1bb a klinikumban tev\u00e9kenyked\u0151 koll\u00e9g\u00e1k fogalmazt\u00e1k meg, ut\u00f3bbiakat pedig hangs\u00falyosabban az elm\u00e9leti szakemberek. Ami viszont hi\u00e1ny\u00e9rzetet keltett, az a vita, vagy tal\u00e1n m\u00e1sk\u00e9pp fogalmazva a hat\u00e9kony eszmecsere. Nem hiszem, hogy egy-egy lev\u00e9l ne \u00e9bresztett volna gondolatokat az olvas\u00f3ban, nem tudom elk\u00e9pzelni, hogy m\u00e1s v\u00e9lem\u00e9nyek ne alakultak volna ki esetleg a fejekben. Mi\u00e9rt nem fogalmazzuk meg \u00e9s \u00edrjuk le ezeket?<\/p>\n
Az egyik szerkeszt\u0151s\u00e9gi lev\u00e9lben p\u00e9ld\u00e1ul a szerz\u0151k hi\u00e1nyolj\u00e1k az \u00faj pszichofarmakonokat, mivel a jelenleg haszn\u00e1latban l\u00e9v\u0151k hat\u00e9konys\u00e1g\u00e1val el\u00e9gedetlenek. Jogos k\u00edv\u00e1nalom? Igen. Ugyanakkor felmer\u00fcl a k\u00e9rd\u00e9s, hogy a mai gy\u00f3gyszerpalett\u00e1t megfelel\u0151en alkalmazzuk-e a betegeinkn\u00e9l. A sikeres ter\u00e1pia \u00e1ltal megk\u00f6vetelten mi alapj\u00e1n diagnosztiz\u00e1lunk? Az egyik levelet k\u00e9rd\u00e9ss\u00e9 transzform\u00e1lva: fenot\u00edpus, genot\u00edpus vagy net\u00e1n endofenot\u00edpus alapj\u00e1n? Mennyire tudunk visszany\u00falni a klasszikus pszichopatol\u00f3gi\u00e1hoz, annak elemeit \u00f6tv\u00f6zz\u00fck-e a leg\u00fajabb biol\u00f3giai ismeretekkel? Milyen szempontokat vesz\u00fcnk figyelembe a gy\u00f3gyszerv\u00e1laszt\u00e1sn\u00e1l? Racion\u00e1lisan d\u00f6nt\u00fcnk-e a d\u00f3zisv\u00e1ltoztat\u00e1s vagy -v\u00e1lt\u00e1s k\u00e9rd\u00e9s\u00e9ben? Gondolunk-e a komorbidit\u00e1sra, komedik\u00e1ci\u00f3ra, az interakci\u00f3kra? Mindehhez rendelkez\u00fcnk-e, mi, pszichi\u00e1terek el\u00e9gs\u00e9ges tud\u00e1ssal a neurol\u00f3giai, belgy\u00f3gy\u00e1szati \u00e9s egy\u00e9b betegs\u00e9gek mibenl\u00e9t\u00e9r\u0151l, az ezek gy\u00f3gy\u00edt\u00e1s\u00e1ban alkalmazott szerekr\u0151l, pszichofarmakol\u00f3giai beavatkoz\u00e1sunk \u201eszomatikus\u201d betegs\u00e9gre, illetve ter\u00e1pi\u00e1j\u00e1ra kifejtett hat\u00e1sair\u00f3l? Kell\u0151 m\u00e9rt\u00e9kben, de l\u00e9p\u00e9st tartunk-e p\u00e9ld\u00e1ul az immunol\u00f3gia vagy az endokrinol\u00f3gia halad\u00e1s\u00e1val? Egy\u00e1ltal\u00e1n, meggy\u0151z\u0151d\u00e9ssel valljuk-e, hogy a pszichi\u00e1tria a medicina r\u00e9sze?<\/p>\n
Visszat\u00e9rve az eredeti k\u00e9rd\u00e9sre: az \u00faj gy\u00f3gyszerre val\u00f3 v\u00e1rakoz\u00e1s k\u00f6zben szintetiz\u00e1ljuk-e ismereteinket a pszichofarmakonok \u00e9s a szervezet egym\u00e1srahat\u00e1s\u00e1r\u00f3l? Azaz felhaszn\u00e1ljuk-e az egy\u00e9nre szabott ter\u00e1pia aktu\u00e1lis lehet\u0151s\u00e9geit? Az egyik utols\u00f3 lev\u00e9l a szem\u00e9lyre szabott kezel\u00e9s alapjaival foglalkozik. (Az egy\u00e9nre szabott kifejez\u00e9st jobbnak tal\u00e1lom, mert egy\u00e9nibb, mint a szem\u00e9lyre szabott). Prec\u00edz \u00e1ttekint\u00e9st ad a farmakogenetik\u00e1r\u00f3l, de az \u201eegy\u00e9nre szab\u00e1shoz\u201d a klinikusnak ismernie kellene a felsz\u00edv\u00f3d\u00e1si viszonyokat, a plazmaszintet, a v\u00e9r-agy g\u00e1t m\u0171k\u00f6d\u00e9s\u00e9t is, nem besz\u00e9lve arr\u00f3l, hogy a gy\u00f3gyszer milyen \u00e1llapotban tal\u00e1lja a k\u00f6zponti idegrendszert, \u00e9s ott milyen hat\u00e1st k\u00e9pes kifejteni (farmakodin\u00e1mia). Mindezek meghat\u00e1roz\u00e1sa a mindennapi gyakorlatban sajnos m\u00e9g nem lehets\u00e9ges, de t\u00f6reksz\u00fcnk-e arra, hogy min\u00e9l hamarabb el\u00e9rhet\u0151k legyenek az ez ir\u00e1ny\u00fa vizsg\u00e1latok? Vannak azonban olyan biomarkerek, klinikai markerek, farmako-anamnesztikus adatok, amelyekb\u0151l esetleg k\u00f6vetkeztet\u00e9seket tudunk levonni. Ismerj\u00fck-e, alkalmazzuk-e ezeket az inform\u00e1ci\u00f3kat? Net\u00e1n klinikai vizsg\u00e1latot tervez\u00fcnk-e ezekben a t\u00e9m\u00e1kban? Vessz\u00fck-e a f\u00e1rads\u00e1got, hogy egy-egy \u00e9rdekesebb, probl\u00e9m\u00e1sabb esetet ismertess\u00fcnk?<\/p>\n
M\u00e1s ter\u00fclet, de nagyon fontos, az ismeretek kommunik\u00e1ci\u00f3ja. Amikor p\u00e9ld\u00e1ul az antidepressz\u00edvumok hat\u00e9konys\u00e1g\u00e1r\u00f3l adunk t\u00e1j\u00e9koztat\u00e1st, akkor vajon egy adott szerr\u0151l besz\u00e9l\u00fcnk, vagy \u00e1ltal\u00e1ban a depresszi\u00f3 farmakoter\u00e1pi\u00e1j\u00e1nak \u201esikertelens\u00e9g\u00e9r\u0151l\u201d? Tudjuk, hogy ez ut\u00f3bbi \u00edgy nem igaz. J\u00f3 kezekben vannak-e a pszichofarmakonok? Megk\u00edv\u00e1nhatjuk-e a csal\u00e1dorvost\u00f3l, hogy prec\u00edz ismeretei legyenek arr\u00f3l a pszichoakt\u00edv szerr\u0151l, amit be\u00e1ll\u00edt? Megengedhet\u0151-e az a tendencia, hogy pszichol\u00f3gusok \u201ezsebb\u0151l\u201d gy\u00f3gyszereljenek betegeket? Egy\u00e1ltal\u00e1n \u201ekiv\u00e1lthat\u00f3-e\u201d a pszichi\u00e1ter pszichol\u00f3gussal? Nagyon fontos k\u00e9rd\u00e9s az oktat\u00e1s. Megfelel\u0151 mennyis\u00e9gben \u00e9s min\u0151s\u00e9gben adjuk-e \u00e1t a pszichofarmakol\u00f3giai tudnival\u00f3kat a gradu\u00e1lis \u00e9s posztgradu\u00e1lis k\u00e9pz\u00e9sben? Tudjuk-e, hogy a fiatal koll\u00e9g\u00e1k honnan \u00e9s milyen ismereteket szereznek? A k\u00e9rd\u00e9s r\u00e1nk, tapasztaltnak mondhat\u00f3 szakemberekre is vonatkozhat. Nem besz\u00e9lve a laikus (\u00fcgyv\u00e9d, szociol\u00f3gus, riporter stb.) \u201ev\u00e9lem\u00e9nyform\u00e1l\u00f3kr\u00f3l\u201d.<\/p>\n
Quo vadis magyar pszichofarmakol\u00f3gia? Jogos a k\u00e9rd\u00e9s, ugyanakkor tudnunk kell, hogy a fentebb felvetett k\u00e9rd\u00e9sek nem magyar specifikumok. P\u00e9ld\u00e1ul a British Journal of Psychiatry az elm\u00falt 2-3 \u00e9vben k\u00f6z\u00f6lt igen hat\u00e1rozott \u00e1ll\u00e1sfoglal\u00e1sokat t\u00f6bbek k\u00f6z\u00f6tt arr\u00f3l, hogy kell-e a pszichi\u00e1ter sz\u00e1m\u00e1ra neurol\u00f3giai ismeret, sz\u00fcks\u00e9ges-e a pszichofarmakon ad\u00e1sa, hat\u00e9konyak-e a rendelkez\u00e9s\u00fcnkre \u00e1ll\u00f3 gy\u00f3gyszerek. \u00c9rdemes elolvasni a szakmailag elismert brit koll\u00e9g\u00e1k v\u00e9lem\u00e9ny\u00e9t. Rem\u00e9lem, a tisztelt olvas\u00f3 velem egy\u00fctt k\u00edv\u00e1ncsian v\u00e1rja a magyar szakemberek reflexi\u00f3it a felvetett gondolatokra.<\/p>\n<\/div>\n
[\/et_pb_toggle][et_pb_blurb title=”The message of the survival curves: I. Composite analysis of long-term treatment studies in bipolar disorder” url=”https:\/\/mppt.hu\/magazin\/pdf\/xiv-evfolyam-3-szam\/frecska.pdf” url_new_window=”on” image=”https:\/\/mppt.hu\/wp-content\/uploads\/2019\/04\/pdf.png” icon_placement=”left” image_max_width=”105%” content_max_width=”1100px” _builder_version=”3.22.7″ header_font=”||||||||” header_font_size=”17px” header_line_height=”1.3em” body_font=”||on||||||” body_line_height=”1.3em” link_option_url=”https:\/\/mppt.hu\/magazin\/pdf\/xiv-evfolyam-3-szam\/frecska.pdf” link_option_url_new_window=”on”]<\/p>\n
Ede Frecska, Attila Istvan Kovacs, Petra Balla, Linda Falussy, Akos Ferencz and Zsofia Varga<\/p>\n
[\/et_pb_blurb][et_pb_toggle title=”Abstract” closed_toggle_text_color=”#000000″ closed_toggle_background_color=”rgba(0,0,0,0)” icon_color=”#0c71c3″ _builder_version=”3.22.7″ title_font=”|600|||||||” title_letter_spacing=”1px” text_orientation=”justified” custom_padding=”0px||10px” border_width_all=”0px” border_width_bottom=”1px”]<\/p>\n
<\/p>\n<\/div>\n
Rationale<\/strong>: There is a shortage of studies analyzing the time course of recurrent episodes and comparing effectiveness of long-term treatments in bipolar disorder. \u2018Number needed to treat\u2019 (NNT) analyses have been proven to be useful for clinically meaningful comparisons, but results vary considerably among studies. The survival curves of different trials also show a great variability preventing reliable conclusions on the time course of maintenance therapies. The variance of survival analyses on long-term medication management can be reduced with increasing the statistical power by combining the life-tables of individual studies.\u00a0Methods<\/strong>: In this study the survival tables of 28 studies on maintenance treatment of bipolar disorder were reconstructed from the published diagrams, and the numbers of relapsed patients in the original studies were estimated for plotting composite survival curves of an inactive, mono- and combination therapy arm. The review was finally based on 5231 subjects.Results<\/strong>: The resulting composite diagrams indicate that within the first year 48% of patients on monotherapy, and 35% on combination therapy experienced recurrence of any affective episode (\u2018early relapsers\u2019). The rest of the patient population was affected by recurrences in a smaller rate over a more extended period of time (\u2018late relapsers\u2019). For a favorable outcome at 40 months of episode prevention in bipolar disorder the NNT was 6 for mono- and 3 for combination therapy. Log-rank analyses of the composite data supported the effectiveness of both medication protocols over placebo, and the superiority of drug combination over monotherapy; though there were some indications of decreased efficacy in the two treatment arms after extended maintenance.\u00a0Conclusions<\/strong>: Composite analysis offers increased statistical power for studying the time course of survival data. Mood episodes in bipolar disorder are likely to recur early on and relapses in \u201creal-life\u201d can be more frequent than the rates published here. Our results favor combination therapy for the long-term management of bipolar disorder. Concerns are expressed that NNT analyses have significant limitations when applied to recurring events with cumulative deterioration instead of cases where cumulative improvement is expected over time.<\/p>\n (Neuropsychopharmacol Hung 2012; 14(3): 155-164; doi: 10.5706\/nph201209001)<\/em><\/p>\n Keywords:<\/strong>\u00a0bipolar disorder, cumulative survival rates, Kaplan-Meier analysis, life tables,\u00a0 [\/et_pb_toggle][et_pb_blurb title=”Marking the Markers of Alzheimer\u2019s: Too good to diagnose, too bad to use?” url=”https:\/\/mppt.hu\/magazin\/pdf\/xiv-evfolyam-3-szam\/olah.pdf” url_new_window=”on” image=”https:\/\/mppt.hu\/wp-content\/uploads\/2019\/04\/pdf.png” icon_placement=”left” image_max_width=”105%” content_max_width=”1100px” _builder_version=”3.22.7″ header_font=”||||||||” header_font_size=”17px” header_line_height=”1.3em” body_font=”||on||||||” body_line_height=”1.3em” link_option_url=”https:\/\/mppt.hu\/magazin\/pdf\/xiv-evfolyam-3-szam\/olah.pdf” link_option_url_new_window=”on”]<\/p>\n Zita Olah, Magdolna Pakaski, Zoltan Janka and Janos Kalman<\/p>\n [\/et_pb_blurb][et_pb_toggle title=”Abstract” closed_toggle_text_color=”#000000″ closed_toggle_background_color=”rgba(0,0,0,0)” icon_color=”#0c71c3″ _builder_version=”3.22.7″ title_font=”|600|||||||” title_letter_spacing=”1px” text_orientation=”justified” custom_padding=”0px||10px” border_width_all=”0px” border_width_bottom=”1px”]<\/p>\n One of the most important neurodegenerative diseases of our time is Alzheimer\u2019s disease, which mainly affects the elderly population. The accumulation of \u03b2-amyloid and tau protein in the brain tissue is the most characteristic pathomechanical event of the disease, later causing neuronal cell death. Setting up an accurate diagnosis of Alzheimer\u2019s disease has essentially changed recently, since besides psychometry, neurochemical and neuroimaging examinations are also gaining greater importance in the clinical routine. Thanks to the widening of diagnostic methods, in the future the disease could be recognised even during the preclinical phase. The most remarkable source of brain-derived compounds is the cerebrospinal fluid. Although obtaining cerebrospinal fluid is greatly unpleasant, it poses a low risk and is frequently used as part of the diagnostic procedure. The assay of cerebrospinal fluid means the identification of the level of \u03b2-amyloid(1-42), tau and phospho-tau and their ratio, but to get more specific and sensitive investigations there is intensive research work both on the utility of their combination and on finding even more specific biomarkers. This review gives a summary of the biomarkers that are being used and being researched for the diagnostic tests of both familial and sporadic forms of Alzheimer\u2019s disease. Other notable sources of neurochemical compounds are the serum and the plasma, however, the identification of their biomarkers is under preclinical examinations. Unfortunately neither the validation of these markers nor the consistent acceptance of the experimental results is possible due to the wide range of protocols in international research. The importance of biomarkers in the development of potential drug candidates is also discussed.<\/p>\n (Neuropsychopharmacol Hung 2012; 14(3): 165-176; doi: 10.5706\/nph201209002)<\/em><\/p>\n Keywords<\/strong>: Alzheimer\u2019s disease, \u03b2-amyloid, tau protein, biomarker, cerebrospinal fluid, diagnostic tool<\/p>\n<\/div>\n [\/et_pb_toggle][et_pb_blurb title=”Associations between season of birth and suicide: a brief review” url=”https:\/\/mppt.hu\/magazin\/pdf\/xiv-evfolyam-3-szam\/antonsen.pdf” url_new_window=”on” image=”https:\/\/mppt.hu\/wp-content\/uploads\/2019\/04\/pdf.png” icon_placement=”left” image_max_width=”105%” content_max_width=”1100px” _builder_version=”3.22.7″ header_font=”||||||||” header_font_size=”17px” header_line_height=”1.3em” body_font=”||on||||||” body_line_height=”1.3em” link_option_url=”https:\/\/mppt.hu\/magazin\/pdf\/xiv-evfolyam-3-szam\/antonsen.pdf” link_option_url_new_window=”on”]<\/p>\n Jon Honer\u00f8d Antonsen, Xenia Gonda, Peter Dome\u00a0and Zoltan Rihmer<\/p>\n [\/et_pb_blurb][et_pb_toggle title=”Abstract” closed_toggle_text_color=”#000000″ closed_toggle_background_color=”rgba(0,0,0,0)” icon_color=”#0c71c3″ _builder_version=”3.22.7″ title_font=”|600|||||||” title_letter_spacing=”1px” text_orientation=”justified” custom_padding=”0px||10px” border_width_all=”0px” border_width_bottom=”1px”]<\/p>\n <\/p>\n<\/div>\n Suicide is a complex behaviour contributing to a significant number of unnecessary deaths worldwide. Accordingly, the quest for suicide risk factors is one of the most intensively developing issues of psychiatric research. In the last few decades a number of interesting results have been published about associations between season of birth (SOB) and several physiological and pathological aspects of human life, while, in regard to neuroscience, several investigations confirmed that SOB is associated with the risk of several major neuropsychiatric disorders and suicide as well. Research concerning the possible causative factors behind these associations were also performed suggesting that SOB-associated factors (including day length; seasonal changes in maternal nutritional status and vitamin D levels; seasonal alterations in incidence of some common infective disorders) contribute to neurochemical and consequentially temperament\/personality trait alterations which may mediate the associations between SOB and psychiatric disorders. Other results indicate an uneven distribution of monoamine metabolism-related genotypes in different birth season cohorts possibly underpinning the effects of SOB. In our narrative review we summarize and discuss the available literature on the relevance of the most important findings concerning the above fields.<\/p>\n (Neuropsychopharmacol Hung 2012; 14(3): 177-187; doi: 10.5706\/nph201209003)<\/em><\/p>\n Keywords<\/strong>: season of birth, month of birth, suicide, affective temperament<\/p>\n<\/div>\n [\/et_pb_toggle][et_pb_blurb title=”Antipsychotic combinations in the treatment of schizophrenia. A review of the literature” url=”https:\/\/mppt.hu\/magazin\/pdf\/xiv-evfolyam-3-szam\/gazdag.pdf” url_new_window=”on” image=”https:\/\/mppt.hu\/wp-content\/uploads\/2019\/04\/pdf.png” icon_placement=”left” image_max_width=”105%” content_max_width=”1100px” _builder_version=”3.22.7″ header_font=”||||||||” header_font_size=”17px” header_line_height=”1.3em” body_font=”||on||||||” body_line_height=”1.3em” link_option_url=”https:\/\/mppt.hu\/magazin\/pdf\/xiv-evfolyam-3-szam\/gazdag.pdf” link_option_url_new_window=”on”]<\/p>\n Gazdag G\u00e1bor, Tolna Judit and Bitter Istv\u00e1n<\/p>\n [\/et_pb_blurb][et_pb_toggle title=”Abstract” closed_toggle_text_color=”#000000″ closed_toggle_background_color=”rgba(0,0,0,0)” icon_color=”#0c71c3″ _builder_version=”4.6.6″ title_font=”|600|||||||” title_letter_spacing=”1px” text_orientation=”justified” custom_padding=”0px||10px” border_width_all=”0px” border_width_bottom=”1px”]<\/p>\n Main indication for antipsychotic medication is the treatment of schizophrenia and other psychotic disorders. Influential protocols in the treatment of schizophrenia recommend the use of <\/span><\/p>\n (Neuropsychopharmacol Hung 2012; 14(3): 189-195; doi: 10.5706\/nph201209004)<\/em><\/p>\n Keywords<\/strong>: antipsychotics, combination, schizophrenia, monotherapy<\/p>\n<\/div>\n [\/et_pb_toggle][et_pb_blurb title=”Relapse prevention in schizophrenia \u2013 A brief review of the literature” url=”https:\/\/mppt.hu\/magazin\/pdf\/xiv-evfolyam-3-szam\/balla.pdf” url_new_window=”on” image=”https:\/\/mppt.hu\/wp-content\/uploads\/2019\/04\/pdf.png” icon_placement=”left” content_max_width=”1100px” _builder_version=”3.22.7″ header_font=”||||||||” header_font_size=”17px” header_line_height=”1.3em” body_font=”||on||||||” body_line_height=”1.3em” link_option_url=”https:\/\/mppt.hu\/magazin\/pdf\/xiv-evfolyam-3-szam\/balla.pdf” link_option_url_new_window=”on”]<\/p>\n Petra\u00a0 Balla and Ede Frecska<\/p>\n [\/et_pb_blurb][et_pb_toggle title=”Abstract” closed_toggle_text_color=”#000000″ closed_toggle_background_color=”rgba(0,0,0,0)” icon_color=”#0c71c3″ _builder_version=”4.6.6″ title_font=”|600|||||||” title_letter_spacing=”1px” text_orientation=”justified” custom_padding=”0px||10px” border_width_all=”0px” border_width_bottom=”1px”]<\/p>\n This article reviews the role of the first and second generation antipsychotics in the long-term <\/span><\/p>\n (Neuropsychopharmacol Hung 2012; 14(3): 197-200; doi: 10.5706\/nph201209005)<\/em><\/p>\n Keywords<\/strong>: first generation antipsychotics, maintenance treatment, schizophrenia, second generation antipsychotics<\/p>\n<\/div>\n [\/et_pb_toggle][\/et_pb_column_inner][\/et_pb_row_inner][\/et_pb_column][et_pb_column type=”1_4″ _builder_version=”3.25″ custom_padding=”|||” custom_padding__hover=”|||”][et_pb_image src=”https:\/\/mppt.hu\/wp-content\/uploads\/2019\/05\/cimlap-2012-szeptember.jpg” align_tablet=”center” align_phone=”” align_last_edited=”on|desktop” _builder_version=”3.23″ box_shadow_style=”preset3″][\/et_pb_image][\/et_pb_column][\/et_pb_section]<\/p>\n","protected":false},"excerpt":{"rendered":" VOLUME 14, ISSUE 3, SEPTEMBER 2012G\u00e1bor Kov\u00e1cs\u00a0 Az elm\u00falt \u00e9vek szerkeszt\u0151s\u00e9gi leveleinek szerz\u0151i a farmakol\u00f3gia-pszichofarmakol\u00f3gia-neurofarmakol\u00f3gia t\u00e1rgy\u00e1ban a t\u00e1gabb \u00e9rtelemben vett \u00e1ttekint\u00e9seken t\u00falmen\u0151en megfogalmazt\u00e1k saj\u00e1t v\u00e9lem\u00e9ny\u00fcket is az \u00e9rintett t\u00e9m\u00e1ban. Pesszimista \u00e9s optimista megk\u00f6zel\u00edt\u00e9sekkel egyar\u00e1nt tal\u00e1lkozhattunk, el\u0151bbieket tal\u00e1n ink\u00e1bb a klinikumban tev\u00e9kenyked\u0151 koll\u00e9g\u00e1k fogalmazt\u00e1k meg, ut\u00f3bbiakat pedig hangs\u00falyosabban az elm\u00e9leti szakemberek. Ami viszont hi\u00e1ny\u00e9rzetet keltett, az […]<\/p>\n","protected":false},"author":4,"featured_media":48319,"comment_status":"closed","ping_status":"closed","template":"","meta":{"_et_pb_use_builder":"on","_et_pb_old_content":"","_et_gb_content_width":"","footnotes":""},"project_category":[63],"project_tag":[],"class_list":["post-49325","project","type-project","status-publish","has-post-thumbnail","hentry","project_category-2012-en"],"_links":{"self":[{"href":"https:\/\/mppt.hu\/en\/wp-json\/wp\/v2\/project\/49325","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/mppt.hu\/en\/wp-json\/wp\/v2\/project"}],"about":[{"href":"https:\/\/mppt.hu\/en\/wp-json\/wp\/v2\/types\/project"}],"author":[{"embeddable":true,"href":"https:\/\/mppt.hu\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/mppt.hu\/en\/wp-json\/wp\/v2\/comments?post=49325"}],"version-history":[{"count":8,"href":"https:\/\/mppt.hu\/en\/wp-json\/wp\/v2\/project\/49325\/revisions"}],"predecessor-version":[{"id":49692,"href":"https:\/\/mppt.hu\/en\/wp-json\/wp\/v2\/project\/49325\/revisions\/49692"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/mppt.hu\/en\/wp-json\/wp\/v2\/media\/48319"}],"wp:attachment":[{"href":"https:\/\/mppt.hu\/en\/wp-json\/wp\/v2\/media?parent=49325"}],"wp:term":[{"taxonomy":"project_category","embeddable":true,"href":"https:\/\/mppt.hu\/en\/wp-json\/wp\/v2\/project_category?post=49325"},{"taxonomy":"project_tag","embeddable":true,"href":"https:\/\/mppt.hu\/en\/wp-json\/wp\/v2\/project_tag?post=49325"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}
maintenance, mood stabilizers, number needed to treat, recurrence<\/p>\n<\/div>\n
antipsychotics in monotherapy. In case of therapy resistance, combination of antipsychotics
is a feasible option. Applying antipsychotics in combination is common in clinical practice,
although existing efficacy and safety data concerning antipsychotic combinations are scarce.
Authors, after reviewing existing scientific data, make attempt to give recommendations for
combined antipsychotic therapy in everyday clinical practice.\u00a0<\/span><\/p>\n
treatment of schizophrenia. The different forms of course, the relationship between maintenance treatment and relapse rates, the influence of depot antipsychotics and adherence on
the outcome, and other predictive factors will be addressed in the paper. The necessity of
a survival meta-analysis is emphasized for the calculation of the \u2018number needed to treat\u2019,
and for a detailed analysis of the time course of recurrences.<\/span><\/p>\n